The role of carfilzomib in treatment of newly diagnosed multiple myeloma
| Autor: | Stefan Knop, Susanne Strifler |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Oncology
Proteasome Endopeptidase Complex Cancer Research medicine.medical_specialty Newly diagnosed Dexamethasone 03 medical and health sciences chemistry.chemical_compound Clinical Trials Phase II as Topic 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Animals Humans Cyclophosphamide Multiple myeloma Clinical Trials Phase I as Topic business.industry Refractory Multiple Myeloma General Medicine medicine.disease Carfilzomib First line treatment Safety profile Treatment Outcome chemistry Cardiovascular Diseases 030220 oncology & carcinogenesis Proteasome inhibitor Multiple Myeloma business Oligopeptides 030215 immunology medicine.drug |
| Zdroj: | Future Oncology. 14:3123-3134 |
| ISSN: | 1744-8301 1479-6694 |
| DOI: | 10.2217/fon-2018-0040 |
| Popis: | Despite improvement of prognosis since approval of proteasome inhibitors and immunomodulatory drugs, myeloma remains largely incurable. The outcome of first-line treatment is known to be crucial for survival and, therefore, implementation of novel strategies remains one of the key aims of clinical myeloma research. Since approval of carfilzomib for relapsed and refractory multiple myeloma, a new therapeutic option with a favorable safety profile regarding neuropathy is available. Regarding its superior response rates and progression-free survival (PFS) when combined with other agents in heavily pretreated patients, the compound rapidly became a matter of great interest in search for first-line treatment. With an ORR up to 98% and promising PFS data, it might become an important partner in treatment of newly diagnosed myeloma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|